These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16296331)

  • 1. [Micrococcus blood stream infection in patients receiving epoprostenol].
    Mitsutake K; Nogami T
    Kansenshogaku Zasshi; 2005 Oct; 79(10):829-30. PubMed ID: 16296331
    [No Abstract]   [Full Text] [Related]  

  • 2. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension.
    Oudiz RJ; Widlitz A; Beckmann XJ; Camanga D; Alfie J; Brundage BH; Barst RJ
    Chest; 2004 Jul; 126(1):90-4. PubMed ID: 15249447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous catheter infections in pulmonary arterial hypertension.
    Gaine S; Gomberg-Maitland M
    Int J Clin Pract Suppl; 2008 Jul; (160):3-4. PubMed ID: 18638169
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative analysis of Micrococcus luteus isolates from blood cultures of patients with pulmonary hypertension receiving epoprostenol continuous infusion.
    Hirata Y; Sata M; Makiuchi Y; Morikane K; Wada A; Okabe N; Tomoike H
    J Infect Chemother; 2009 Dec; 15(6):424-5. PubMed ID: 20012737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bloodstream infections due to Micrococcus spp and intravenous epoprostenol.
    Valdivia-Arenas MA
    Infect Control Hosp Epidemiol; 2009 Dec; 30(12):1237. PubMed ID: 19888847
    [No Abstract]   [Full Text] [Related]  

  • 6. Micrococcus infection in patients receiving epoprostenol by continuous infusion.
    Yap RL; Mermel LA
    Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):704-5. PubMed ID: 14576986
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension.
    Akagi S; Matsubara H; Ogawa A; Kawai Y; Hisamatsu K; Miyaji K; Munemasa M; Fujimoto Y; Kusano KF; Ohe T
    Circ J; 2007 Apr; 71(4):559-64. PubMed ID: 17384460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
    Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
    Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overdosing with prostacyclin in primary pulmonary hypertension.
    Wasserman K; Oudiz R
    J Am Coll Cardiol; 2000 Jun; 35(7):1995-6. PubMed ID: 10841256
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostacyclin withdrawal in pulmonary hypertension #264.
    Bartlett C; Landzaat L;
    J Palliat Med; 2013 Feb; 16(2):204-5. PubMed ID: 23336356
    [No Abstract]   [Full Text] [Related]  

  • 11. Low incidence of catheter-related complications in patients with advanced pulmonary arterial hypertension undergoing continuous epoprostenol infusion.
    Nagai T; Kohsaka S; Anzai T; Yoshikawa T; Fukuda K; Sato T
    Chest; 2012 Jan; 141(1):272-273. PubMed ID: 22215838
    [No Abstract]   [Full Text] [Related]  

  • 12. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
    Horn EM; Barst RJ; Poon M
    Chest; 2000 Oct; 118(4):1229-30. PubMed ID: 11035709
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Complications with the Delivery of Inhaled Epoprostenol in the Operating Room.
    Bhatt AM; Stein EJ
    Anesthesiology; 2017 Aug; 127(2):383. PubMed ID: 28323647
    [No Abstract]   [Full Text] [Related]  

  • 14. The "bouncing" catheter.
    Malaczynska-Rajpold K; Kurzyna M; Koteja A; Torbicki A; Mularek-Kubzdela T
    Cardiol J; 2016; 23(5):552-553. PubMed ID: 27723062
    [No Abstract]   [Full Text] [Related]  

  • 15. [A case of primary pulmonary hypertension treated by long-term continuous administration of epoprostenol].
    Yano S; Kobayashi K; Kato K; Tatsukawa T; Ikeda T
    Nihon Kokyuki Gakkai Zasshi; 2005 Jun; 43(6):354-9. PubMed ID: 15997785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary pulmonary hypertension treated with short-term epoprostenol infusion.
    Shiota Y; Mikawa Y; Arikita H; Nakashima T; Horita N; Hiyama J; Ono T; Yamakido M
    Intern Med; 2003 Sep; 42(9):824-6. PubMed ID: 14518669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.
    Bakst AE; Gaine SP; Rubin LJ
    Chest; 1999 Oct; 116(4):1127-9. PubMed ID: 10531185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of pulmonary hypertension with inhaled agents in the pediatric intensive care unit.
    Gillis HC; Fischer G; Gupta S
    Am J Health Syst Pharm; 2018 Feb; 75(4):171-172. PubMed ID: 29436464
    [No Abstract]   [Full Text] [Related]  

  • 19. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
    Gómez Sánchez MA
    Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose epoprostenol improved pulmonary hypertension in a patient with systemic lupus erythematosus.
    Matsukawa Y; Igei K; Nozaki T; Ohki T; Shimizu T; Kitamura N; Mitamura K; Takei M; Kasamaki Y; Sawada S
    Clin Rheumatol; 2007 Apr; 26(4):582-3. PubMed ID: 16391888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.